Health Care & Life Sciences » Biotechnology | Biogen Idec Inc.

Biogen Idec Inc. | Mutual Funds

Mutual Funds that own Biogen Idec Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Vanguard PRIMECAP Fund
9,221,680
4.58%
15,180
4.68%
06/30/2018
Vanguard Total Stock Market Index Fund
5,303,453
2.63%
21,114
0.25%
07/31/2018
Vanguard 500 Index Fund
3,821,107
1.9%
4,252
0.3%
07/31/2018
Vanguard Health Care Fund
3,592,903
1.78%
0
2.52%
06/30/2018
ClearBridge Aggressive Growth Fund
3,170,327
1.57%
-14,514
9.07%
12/31/2017
iShares Nasdaq Biotechnology ETF
2,373,169
1.18%
-31,038
8.56%
09/06/2018
Vanguard Capital Opportunity Fund
2,331,100
1.15%
-25,000
4.38%
06/30/2018
SPDR S&P 500 ETF
2,328,846
1.15%
26,908
0.3%
09/06/2018
Vanguard Institutional Index Fund
2,041,057
1.01%
1,990
0.3%
07/31/2018
Government Pension Fund - Global (The)
2,033,992
1.01%
51,141
0.09%
12/31/2017

About Biogen Idec

View Profile
Address
225 Binney Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.biogen.com
Updated 07/08/2019
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.